CORDIS
EU research results

CORDIS

English EN

PharmaLedger

Project information

Grant agreement ID: 853992

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2022

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 20 920 901,75

  • EU contribution

    € 8 290 693,75

Coordinated by:

UNIVERSIDAD POLITECNICA DE MADRID

Spain

Project description

English EN

A digital boost for the healthcare industry

The internet and other digital advances are playing an increasingly bigger role in daily life by enabling industries to innovate, thus delivering improved services to both consumers and providers. Unfortunately, the healthcare industry hasn’t caught up as fast. The EU-funded PharmaLedger project will create and introduce a blockchain-based framework that will efficiently digitalise the healthcare industry and empower patients. It plans to do this by bringing together 29 partners including 10 EU member states, several large pharmaceutical companies and many other specialists in blockchain development, security, privacy and business intelligence. The goal of the project is to provide a widely trusted platform that will support the design and adoption of blockchain-enabled healthcare solutions while accelerating delivery of innovation that will benefit the entire ecosystem, from manufacturers to patients.

Coordinator

UNIVERSIDAD POLITECNICA DE MADRID

Address

Calle Ramiro De Maeztu 7 Edificio Rectorado
28040 Madrid

Spain

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 873 750

Participants (27)

NOVARTIS PHARMA AG

Switzerland

PDM E FC PROJECTO DESENVOLVIMENTO MANUTENCAO FORMACAO E CONSULTADORIALDA

Portugal

EU Contribution

€ 648 125

ROMSOFT SRL

Romania

EU Contribution

€ 1 157 500

ARTEEVO TECHNOLOGIES LTD

Israel

EU Contribution

€ 906 250

TECHNOVATIVE SOLUTIONS LTD

United Kingdom

EU Contribution

€ 910 625

EKON MODELING SOFWARE SYSTEMS LTD*EKON

Israel

EU Contribution

€ 456 250

ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS

Greece

EU Contribution

€ 282 500

ABBVIE INC

United States

ASTRAZENECA AB

Sweden

BAYER AKTIENGESELLSCHAFT

Germany

GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD.

United Kingdom

JANSSEN PHARMACEUTICA NV

Belgium

MERCK SHARP & DOHME CORP

United States

NOVO NORDISK A/S

Denmark

PFIZER LIMITED

United Kingdom

F. HOFFMANN-LA ROCHE AG

Switzerland

UCB BIOPHARMA SRL

Belgium

KATHOLIEKE UNIVERSITEIT LEUVEN

Belgium

EU Contribution

€ 338 500

ONORACH LTD

United Kingdom

EU Contribution

€ 511 568,75

NATIONAL RESEARCH AND DEVELOPMENT INSTITUTE FOR CRYOGENICS AND ISOTOPIC TECHNOLOGIES ICSI RM VALCEA

Romania

EU Contribution

€ 370 000

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT

Germany

EU Contribution

€ 307 500

DIMOKRITIO PANEPISTIMIO THRAKIS

Greece

EU Contribution

€ 216 250

HOSPITAL DO ESPIRITO SANTO DE EVORA EPE

Portugal

EU Contribution

€ 351 250

OSPEDALE PEDIATRICO BAMBINO GESU

Italy

EU Contribution

€ 347 500

IMPRENSA NACIONAL - CASA DA MOEDA, S. A.

Portugal

EU Contribution

€ 365 625

FORUM EUROPEEN DES PATIENTS (FPE)

Luxembourg

EU Contribution

€ 143 750

EUROPEAN FORUM FOR GOOD CLINICAL PRACTICE

Belgium

EU Contribution

€ 103 750

Project information

Grant agreement ID: 853992

Status

Ongoing project

  • Start date

    1 January 2020

  • End date

    31 December 2022

Funded under:

H2020-EU.3.1.7.

  • Overall budget:

    € 20 920 901,75

  • EU contribution

    € 8 290 693,75

Coordinated by:

UNIVERSIDAD POLITECNICA DE MADRID

Spain